Clinical trial
Biological Therapy in Treating Patients With Primary or Advanced Glioma
NCT00003067 · Weill Medical College of Cornell University, Other · Suspended
Key facts
| NCT number | NCT00003067 |
|---|---|
| Title | Biological Therapy in Treating Patients With Primary or Advanced Glioma |
| Official title | Intracavitary Interleukin-2 (IL-2) and Lymphokine-Activated Killer (LAK) Cell Therapy for Malignant Gliomas |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Status | Suspended |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological |
| Interventions | aldesleukin, lymphokine-activated killer cells |
| Start date | Jul 1, 1997 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: